Modulation of Condensate Composition for Drug Discovery

CD BioSciences offers a variety of condensate-based drug discovery strategies to achieve repair condensatopathy, disrupt the normal function of condensates associated with disease, and prevent targets from acting by disabling them in their natural condensates or by separating them from their natural condensates. Here, we help you with drug development by modulating the condensate composition.

Introduction of Biomolecular Condensate Composition

Individual biomolecular condensates have a specific composition, often concentrating ten to hundreds of different proteins and often containing RNA molecules. In addition, studies have shown that other biomolecules such as amino acids, sugars, metabolic intermediates, and enzymatic cofactors may be present in the condensate. The structure and function of biomolecular condensates are directly related to the composition of the condensate community. Mislocalized proteins far from their physiological condensates communities or in unnatural condensates can drive pathological disease mechanisms. Changes in condensates composition can affect many characteristics, from material properties (e.g. viscosity and surface tension) to kinetics and the ability to respond to environmental stimuli (e.g. persistence and aging) to individual components of enzymatic activity.

Fig. 1. (Super)molecular structural properties that define dense phases. (Peran I, et al, 2020)

Our Solutions

In the field of drug discovery, our experts are increasingly interested in modulating condensate composition as a new therapeutic strategy. CD BioSciences is committed to developing innovative therapeutics by modulating condensate composition aimed at restoring normal physiological states, correcting abnormal protein localization, and inhibiting disease-associated condensates. Our solutions for modulating condensate composition include:

• Targeting Abnormal Protein Localization
  Abnormal protein localization is a hallmark of many diseases, including cancer. CD BioSciences is at the forefront of developing small molecule localization condensate modification therapies that can undo protein mislocalization. Our solutions help mislocalized proteins return to their natural position in the nucleolus and nucleus, restoring normal cellular function and inhibiting disease progression.
• Inhibition of Pathological Condensates
  Pathological condensates are characterized by dysregulated composition and function that can drive disease mechanisms. Our experts can restore the physiological state and halt disease progression by designing condensate modification therapies that disrupt specific protein-protein or protein-RNA interactions within the condensate.
• Overcoming Drug Resistance
  Drug resistance is a major challenge for cancer treatment. CD BioSciences recognizes the role of condensates in drug resistance mechanisms and is committed to developing strategies to overcome this resistance. We offer the use of localization condensate  modification therapies to reposition activators away from condensates, thereby restoring active signaling to overcome drug resistance.
• Anticancer Drug Specificity and Toxicity
  Certain platinum compounds induce nucleolar stress and trigger changes in condensate composition, particularly in the nucleolus. These changes can affect the localization and function of nucleolar proteins and lead to cell death. CD BioSciences utilizes a  cutting-edge condensate-based drug discovery platform to design more effective and targeted platinum-based drugs to improve therapeutic outcomes. We aim to improve the specificity and reduce the toxicity of these drugs by modulating condensate composition.

Modulation of condensate composition for drug discovery is an emerging and promising approach in biotechnology. CD BioSciences recognizes the potential of this strategy and has been actively involved in the development of innovative solutions for a variety of disease mechanisms, including aberrant protein localization, pathological condensates, drug resistance, and drug specificity. Through the design of localizer condensate modification therapies and the understanding of condensate structure-function relationships, we aim to pave the way for novel therapeutic interventions and contribute to improved patient outcomes. If you are interested in our solutions, please contact us now to seize new drug development opportunities.